Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 14 Article 3
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 14, 03 April 2003

Citation style for this article: Seventh WHO annual report on global TB control. Euro Surveill. 2003;7(14):pii=2197. Available online:

Seventh WHO annual report on global TB control

Editorial team (, Eurosurveillance editorial office.

To mark world TB day, 24 March 2003, the World Health Organization (WHO) has published the seventh annual report on global tuberculosis (TB) control. This report aims to share information from national TB control programmes, and includes data on case notifications and treatment outcomes. It also provides analysis of plans, finances and constraints on DOTS (directly observed treatment-short course) expansion for the 22 high burden countries in order to assess progress toward global targets for case detection (70%) and treatment success (85%).

According to this report, there were an estimated 8.4 million new cases of tuberculosis in 2001. Total notifications in Europe represent 10% of global notifications in 2001, with case detection over 70% in 35 of the 51 countries in the WHO European region, according to revised estimates. The tuberculosis epidemic is still growing by approximately 0.4%/year, but much faster in sub-Saharan Africa and in countries of the former Soviet Union (1). The TB epidemic is closely linked to HIV and poverty in sub-Saharan Africa, and is exacerbated by disruption to public health services in many countries of the former Soviet Union (2). In some sub-Saharan African countries with high HIV prevalence, TB rates have quadrupled since the mid 1980s, threatening to overwhelm well established TB control programmes. AntiTB drug resistance, an increasingly recognised effect of inappropriate TB control will be dealt with in a specific report expected to be published by the end of 2003.

The number of countries implementing DOTS has increased, bringing the total to 155 out of 210 countries. By the end of 2001, 61% of the world's population lived in DOTS areas.

Two thirds (67%) of the additional smear-positive cases reported under DOTS in 2001 (compared with 2000) were found in India alone. There were smaller but marked improvements in case detection in Myanmar, the Philippines, and Thailand. Other high burden countries made minor gains in case detection, though Pakistan and Brazil reported significant increases in the geographical coverage of DOTS.

Treatment success under DOTS for the 2000 cohort was 82% on average, and has moved closer to the 85% target as the patient population has grown in size. In the African region, treatment success was only 72%.

In the WHO European region, DOTS coverage exceeded 90% of the population in 14 of the 22 countries (five in the West, five in the Centre, and four in the East) in 1999 (3). As DOTS programmes have expanded geographically, the proportion of estimated cases found within DOTS areas has remained constant at 40-50%. If the 70% target is to be met, DOTS programmes must improve case finding within designated DOTS areas. The constraints on DOTS expansion most often identified were lack of qualified staff, insufficient preparation for decentralisation, non-compliance of the private sector with DOTS, inadequate health infrastructure, and weak political commitment.

The EuroTB annual report 2000 ( includes data on treatment outcome for TB cases notified in 1999 in 30 of the 51 countries of the WHO European Region.


  1. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2003. Geneva, Switzerland, WHO/CDS/TB/2003.316. (
  2. World Health Organization. WHO reports 10 million TB patients successfully treated under "DOTS" 10 years after declaring TB a global emergency (press release) 24 March 2003. (
  3. Infuso A, Falzon D, Veen J. World TB day, 24 March 2003 and TB surveillance in Europe. Eurosurveillance Weekly 2003; 7: 030320 (

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.